EFFICACY AND SAFETY OF SODIUM-GLUCOSE CO-TRANSPORTER (SGLT2 ) INHIBITORS ON CARDIOVASCULAR AND RENAL OUTCOMES IN OBESE DIABETIC PATIENTS, A RETROSPECTIVE COHORT ANALYSIS
Main Article Content
Keywords
Abstract
Individuals with both obesity and type 2 diabetes mellitus (T2DM) face an elevated risk of developing cardiovascular and kidney-related complications. SGLT2 inhibitors, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been found to have promising effects on cardiovascular health and renal function in this high-risk population. By inhibiting SGLT2, works to reduce glucose reabsorption in the kidneys which in turn can lead to improved glycemic control, weight loss and reduced blood pressure. These effects contribute to its beneficial impact on cardiovascular outcomes and kidney function, making it a valuable treatment option for individuals with obesity and T2DM who are at risk of these complications. Objective: This study aimed to assess the impact of SGLT2 inhibitors on cardiovascular and renal outcomes in patients with obesity and type 2 diabetes. Methodology The study involved 500 adults with obesity and type 2 diabetes who received SGLT2 inhibitors treatment for a minimum of 6 months. Data collected include demographic data, clinical information and treatment records. The primary focus was on changes in cardiovascular parameters and renal function, assessed at 1 week, 1 month, 3 months and 6 months after starting treatment. Secondary outcomes included hospitalization for heart failure, mortality rates and safety events. Study place and duration The study included electronic medical records of patients treated at Jinnah postgraduate medical centre between January 2022 to December 2024. Results: The study found that SGLT2 inhibitors therapy for 6 months led to significant reductions in blood pressure and body weight. Renal function improved, with increased eGFR and decreased serum creatinine levels. Glycated hemoglobin levels initially rose but later decreased. Albuminuria decreased modestly over time. Conclusions SGLT2 inhibitors shows promise in improving cardiovascular and renal outcomes in patients with obesity and type 2 diabetes, warranting further research to optimize its therapeutic potential and explore long-term benefits
References
2. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657
3. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular out- comes in type 2 diabetes. N EnglJ Med 2019; 380: 347–357
4. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295–2306
5. Heerspink HJ, Perkins BA, Fitchett DH et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752–772
6. Thomson SC, Rieg T, Miracle C et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75–R83
7. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587–597
8. van Bommel EJM, Muskiet MHA, van Baar MJB et al. The renal hemody- namic effects of the SGLT2 inhibitor dapagliflozin are caused by post- glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double- blind RED trial. Kidney Int 2020; 97: 202–212
9. Cherney DZI, Dekkers CCJ, Barbour SJ et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 2020; 8: 582–593
10. Randomised placebo-controlled trial of effect of ramipril on decline in glo- merular filtration rate and risk of terminal renal failure in proteinuric, non- diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857–1863
11. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insuffi- ciency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 1996; 334: 939–945
12. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for ad- vanced chronic renal insufficiency. N Engl J Med 2006; 354: 131–140
13. Heerspink HJL, Stefansson BV, Chertow GM et al. Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant 2020; 35: 274–282
14. Bakris GL, Agarwal R, Anker SD et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol 2019; 50: 333–344
15. Heerspink HJL, Andress DL, Bakris G et al. Rationale and protocol of the study of diabetic nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab 2018; 20: 1369–1376
16. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11: 749–761
17. ClinicalTrials.gov. A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW) (NCT03819153).
18. Lv J, Zhang H, Wong MG et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017; 318: 432–442
19. Rauen T, Eitner F, Fitzner C et al. Intensive supportive care plus immuno- suppression in IgA nephropathy. N Engl J Med 2015; 373: 2225–2236
20. Barratt J, Rovin B, Diva U et al. Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial). Kidney Int Rep 2019; 4: 1633–1637
21. ClinicalTrials.gov. Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy (Nefigard) (NCT03643965). 2020
22. Heerspink HJL, Parving HH, Andress DL et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393: 1937–1947
23. AstraZeneca. Farxiga Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients with Chronic Kidney Disease. 2020
24. Lambers Heerspink HJ, Weldegiorgis M, Inker LA et al. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis 2014; 63: 244–250
25. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017; 46: 462–472
26. Sharma SG, Bomback AS, Radhakrishnan J et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013; 8: 1718–1724
27. ClinicalTrials.gov. A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT) (NCT03762850). 2020; 341: 2125–2136.
28. Trachtman H, Nelson P, Adler S et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018; 29: 2745–2754
29. ClinicalTrials.gov. Study of Sparsentan in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX). 2022
30. Lazarus B, Wu A, Shin JI et al. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based co- hort study. JAMA Intern Med 2018; 178: 903–910
31. Heerspink HJL, Andress DL, Bakris G et al. Baseline characteristics and en- richment results from the SONAR trial. Diabetes Obes Metab 2018; 20: 1829–1835
32. Bayer’s Finerenone Meets Primary Endpoint in Phase III FIDELIO-DKD Renal Outcomes Study in Patients with Chronic Kidney Disease and Type 2 Diabetes. 2020
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.